SLS
SLS Stock Tracks Worst Month Since March: Investor Slashes Stake By Over 30% As Quiet Period Begins Ahead Of AML Readout
Article Summary
SELL- Sellas Life Sciences (NASDAQ: SLSL) fell 13% in June as an institutional investor trimmed more than 30% of its stake and SELLAS Life Sciences Group entered a quiet period ahead of key acute myeloid leukemia (AML) readout, with the stock down 13% year-to-date as Regal, its Phase 3 trial evaluating Galinpepimut-S as a maintenance therapy for AML patients in second complete remission, approaches the 80th event required to trigger final analysis after previously reaching 78.
- The institutional stake cut comes as Sellas CEO Angelos Stergiou warned investors not to treat slower event accumulation as proof of better survival as the company remains blinded.
- The company has stopped providing trial-specific updates and is focusing on preparations for database lock, regulatory work for a potential biologics license application, and continued development of SLS009, its second AML candidate.
- Regal would meet its objective if GPS delivers median overall survival of 12.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 113.2% | 20% | 100.0 ptsMassive Upside (113.2%) - Target: $27.50 vs Current: $12.90 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -18.8% | 15% | 40.0 ptsMild Pullback (-18.8%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About SLS
- SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States.
- The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
- It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology.
- SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.